Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation

Table 1 Epidemiologic parameters and annual transition probabilities used in the model

Parameter	Base assumptions	Range for sensitivity analysis	Source
Prevalence of HBsAg among pregnant women	0.047	0.025–0.1	[3]
Prevalence of HBeAg among HBsAg positive mothers	0.116	0.05–0.25	[4]
Risk of perinatal transmission (HBeAg +)	0.279	0.1–0.6	[4]
Risk of perinatal transmission (HBeAg−)	0.08	0.02–0.29	[4]
Acute symptomatic cases (for children of HBeAg + mothers)	0.01	–	[4]
Acute symptomatic cases (for children of HBeAg − mothers)	0.05	–	[23]
Fulminant infections among symptomatic cases	0.001	–	[15]
Risk of infant death from fulminant infection	0.7	–	[15]
Risk of infant chronic infection among survivors of fulminant infection	0.33	–	[15]
Risk of chronic HBV infection after perinatal infection	0.9	–	[4]
Chronic HBV infected individuals requiring antiviral treatment (CAH)	0.25	–	[20]
Inactive carriers among individuals with chronic HBV infection	0.75	–	[20]
Annual transition probabilities and disease related mortality
Inactive carrier to
CAH	0.03	–	[23]
Compensated cirrhosis	0.007	–	[24]
HCC	0.0006	–	[24]
CAH to^a			[24]
Inactive carrier	0.55	0.3–0.7	[24]
Compensated cirrhosis	0.0024	0.0012–0.0036	[24]
HCC	0.003	0.002–0.007	[24]
Compensated cirrhosis to
Decompensated cirrhosis	0.035	–	[23]
HCC	0.033	–	[23]
Regression	0.24	–	[24]
Decompensated cirrhosis to
Disease specific death	0.28	–	[23]
HCC	0.15	–	[23]
HCC to
Disease specific death	0.29	–	[23]
Vaccine effectiveness	0.72	0.6–0.8	[27]
Vaccine utilization	0.5	0.1–0.66^b	[14]

^aIn our model, patients with chronic active hepatitis (CAH) are eligible for antiviral treatment therefore we used transition probabilities of treated patients
^bThe highest vaccine utilization rate was based on administrative report for facility delivery in Ethiopia

ISSN: 1478-7547